iBio enters collaboration agreement with AstralBio

iBio announces that it has entered into a collaboration agreement with AstralBio to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions. The goal of this transformative collaboration is to rapidly build a novel, best-in-class cardiometabolic disease portfolio by combining iBio‘s ability to create antibodies against hard-to-drug targets with AstralBio’s significant biologics experience and drug development expertise. As part of the collaboration, iBio has granted an exclusive license to its AI-powered technology to identify and engineer four targets for the treatment of cardiometabolic disease. As a result of this collaboration, iBio and AstralBio have agreed to initiate the development of a novel lead program focused on targeting the transforming growth factor beta superfamily for the treatment of muscle wasting and obesity.